Special Issue

Roles of p53 Family in Cancers and Their Therapeutic Approaches

Message from the Guest Editors

Throughout history, Chinese philosophers have used the concept “Yin” and “Yang” to describe inseparable opposites. The Yin represents dark or negative imagery, while the Yang represents light or positive imagery. The p53 family has the following three members: p53, p63 and p73. In cancer cells, the wild types of p53 or TA isoforms of p63 and p73 are described as the “Yin” and are used to block cancer progression. Most of the mutations of p53 or shorten isoforms of p53 family members (Δ133p53 and Δ160p53, ΔNp63 and ΔNp73) are described as the “Yang” and are used to promote cancer progression. The identification of the ways in which we can target mutant p53 or activate either p63 or p73 is purpose of cancer therapy. The Special Issue seeks to collect manuscripts (original research or reviews) on all p53 family members to study the “Yin”or “Yang” roles of p53 or p63 or p73 in cancers.

Guest Editors

Dr. Bi-He Cai
School of Medicine, I-Shou University, Kaohsiung City 82445, Taiwan
Dr. I-Lun Hsin
Institute of Medicine, Chung Shan Medical University, Taichung City 40201, Taiwan

Deadline for manuscript submissions

closed (31 December 2024)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/166729

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).